The band has launched a Kickstarter campaign to raise the $12,000 needed to fulfill their vision for their new record. As Hayley Jane and company explain in the video on the campaign’s page, Gasoline was completed on a very tight schedule with limited funds, and they are hoping to be able to give their new release the time, effort, and resources it deserves in order to make a high-quality, professional product. With Turkuaz‘s Craig Brodhead handling producing duties, the group plans to head to Syracuse, NY’s More Sound Recording Studios this August to track the as of yet untitled new album.The band is offering an array of fun prizes for different donation levels, including free digital downloads, signed physical copies of both the new album and Gasoline, tickets to an upcoming show of your choice, Primates merch, personal mentions in the “Thank You” section of the new album’s liner notes, personalized thank you songs and videos from the band, an original song about you or a loved one, and even a full live performance at your home!For all the info on the different donation/prize levels, and to donate to the project, visit Hayley Jane and the Primates’ Kickstarter Page.Be sure not to miss Hayley Jane and the Primates when they hit the Brooklyn Bowl in Brooklyn, NY on Wednesday, July 6th! With Elise Testone and Hayley Jane on the same lineup, you know it’s going to be a party! Tickets are available here. Since the release of their last record, Gasoline, in 2014, Boston-based festival circuit favorites Hayley Jane and the Primates have brought their signature brand of genre-blending, vaudevillian story-centered live shows to audiences all over the country. Now, the band is ready to take their road-tested material to the studio, and they are reaching out to their ever-growing fan base to help fund the project.
Omid Farokhzad’s vision of medicine’s future sounds a lot like science fiction.He sees medicine scaled down, with vanishingly small nanoparticles playing a big role, delivering drug doses measured in molecules directly to cancerous tumors.He sees “theranostic” particles that not only deliver nanotherapy, but also beam back diagnostic images of changing tumor cells. He sees “smart” nanoparticles that release tiny doses of drugs, such as insulin, in response to body conditions, like changing blood sugar levels.Farokhzad sees nanoparticle-based vaccines that can take the joy out of smoking and reverse allergies, and the development of therapeutic nanoparticles that can be taken orally instead of injected, opening whole new classes of medications, like cholesterol-lowering statins, to nanoparticle therapy.An associate professor of anesthesia at Harvard Medical School (HMS) and Harvard-affiliated Brigham and Women’s Hospital (BWH), Farokhzad sees these things because he’s helping bring them to reality. Of the seven targeted nanoparticle-based drug candidates currently in human trials, two are based on technologies developed in part in his lab.“I think the medicine my own kids will see in the next 30 to 40 years will be very different from what we practice today,” said Farokhzad, the director of the Brigham’s Laboratory of Nanomedicine and Biomaterials. “Targeted therapies will be the mainstay of treatment for almost all diseases.”Nanoparticles are molecular-scale capsules that can deliver tiny payloads, such as anti-cancer drugs, into the body. A common method uses fat molecules to create the particles, which release the drugs inside when the fat breaks down. Farokhzad, building on work by scientist Robert Langer at the Massachusetts Institute of Technology, has developed controlled-release nanoparticles made of polymers instead of fat. These better resist breakdown and so release drugs over longer periods.If the disease doesn’t kill you …Using a controlled-release nanoparticle in therapy has several advantages over conventional drug delivery, Farokhzad said. Particles with molecules that bind to the outside of cancer cells can target a tumor cell and release drugs directly to the malignancy. In addition, the particles’ extended survival in the bloodstream extend the tumor cells’ exposure to the anti-cancer drug, delivering a greater cumulative dose to the tumor even while lowering the toxicity to the rest of the body.In traditional chemotherapy, for example, doctors blast a patient’s entire body with chemicals in an effort to kill tumor cells. Almost all of the drug, however — upwards of 99 percent, Farokhzad said — misses the tumor entirely. Instead, the highly toxic chemicals hit other organs and tissues, forcing physicians into a high-wire act balancing tumor-killing effectiveness and toxicity, which can lead to a range of side effects, and even kill the patient.In addition, Farokhzad said, the traditional chemo infusion results in a short-duration pulse during which the tumor sees most of the drug. Concentrations then typically fall quickly as the body clears away the chemical.In controlled-release therapy, the nanoparticle concentration is also highest in the blood immediately after infusion, but because the drug is released from the particles more slowly, its peak concentration — and its highest toxicity — is lower, blunting unwanted side effects.At the tumor site, the opposite happens. The nanoparticles’ ability to lock onto tumor cells delivers between five and 10 times the dose of traditional chemotherapy at any moment. And because particles circulate in the blood longer, the tumor’s exposure is also longer.“A tumor sees a materially increased drug concentration compared with the drug given in conventional form and the rest of the body sees about the same level of the drug,” Farokhzad said. “[But] it’s being delivered much more gently over time.”Two potential therapies based on work in Farokhzad’s lab are in human testing. The first, BIND-014, uses targeted nanotherapy for lung and prostate tumors. The drug candidate recently passed phase 1 trials, which are focused on a drug’s safety, and entered phase 2 trials, which measure the therapy’s effectiveness. Farokhzad said the molecular target on the prostate cancer cell is also found on the cells of tumor blood vessels, giving the therapy potentially broader cancer-fighting applications.Two potential therapies based on work in Farokhzad’s lab are in human testing. The first, BIND-014, uses targeted nanotherapy for lung and prostate tumors. The drug candidate recently passed phase 1 trials, which are focused on a drug’s safety, and entered phase 2 trials, which measure the therapy’s effectiveness. Stephanie Mitchell/Harvard Staff PhotographerThe second therapy, which is in phase 1 trials, is a nicotine nanoparticle vaccine, meant to help smokers quit and prevent relapse for those who have done so. The vaccine works by sensitizing the immune system to nicotine, a small molecule that normally escapes the immune system on its way to the brain’s pleasure centers. The vaccine makes nicotine visible to the immune system, clearing it from the body and removing the pleasurable sensation it causes.The trials are being run by two of the three companies Farokhzad has founded since 2007. The first, Bind Therapeutics, was established to develop the early promise of targeted nanoparticles for cancer treatment. The second, Selecta Biosciences, was similarly founded to pursue nanoparticle-based vaccine development. The third company, Blend Therapeutics, is designing drug molecules that are optimized from the start to work with nanoparticles to target infectious diseases, inflammation, pain, and cancer.Passing the “who cares’’ testFarokhzad, who received his M.D. from Boston University, was drawn to nanoparticle research during his residency at BWH. In addition to his clinical duties, he was conducting research on the transcription factors that regulate the expression of genes involved in myeloid differentiation, but he was looking for a project that had a near-term potential to improve the lives of patients he was seeing in the clinic every day.“I was just stepping back … and looking at the big picture. If I did everything well and understood the transcriptional regulation of these genes, whose lives would it change? At the end of the day, does it pass the ‘who cares’ test?” Farokhzad said. “I wanted things that had a human application, a bench-side innovation that could go to the bedside.”Farokhzad heard about Langer, who runs the largest biomedical engineering lab in the world and has conducted pioneering work in tissue engineering and drug delivery systems, including long-lasting nanoparticles. He contacted Langer, who agreed to take him on as a postdoc.Farokhzad explored creating nanoparticles with nucleic acids on their surface that bind to specific sites on cancer cells, like a key that fits a lock, as he described it. In 2004, he demonstrated that the technique worked on cells in a lab dish and, a year later, delivered a talk at an international cancer conference in Paris describing experiments showing that the technique worked in animals.“I thought if there was a way to spatially control which tissues saw more of the drug, it would be a paradigm shift,” Farokhzad said.The response was immediate. Conference organizers chose his work to be among the handful of findings they promoted out of the conference, and the media attention drew venture capitalists looking to finance the next big discovery.Farokhzad, who had left Langer’s lab in 2004 to start his own lab at the Brigham, turned to Langer, who he knew had started several companies. Together, the two co-founded Bind Therapeutics.“He totally took it to a huge new level,” Langer said of Farokhzad’s development of earlier nanoparticle research. “Omid is passionate about making discoveries into new products that can help people’s lives.”Farokhzad not only took from Langer’s lab an interest in nanoparticles, he also adopted Langer’s view that private industry is an essential partner in bringing discoveries to the patient.“My philosophy has been: ‘How do you get these things to the public?’ Our lab is a pretty good size and does pretty well in grants, but you can only go so far in what you expect students to do,” Langer said. “These companies provide a terrific vehicle for bringing these ideas from the lab to the clinic.”Tools to deliver needed drugsToday, Farokhzad’s lab takes up one entire floor plus part of another in the Brigham’s Medical Research Building in Boston’s Longwood Medical Area. Its 30 investigators, including fellows and students, explore ways to make nanoparticles with novel properties that might make them useful in therapy. One of his longtime fellows, Jinjun Shi, has received an appointment as an assistant professor of anesthesia and is moving upstairs to open his own lab.Nanoparticles, Farokhzad said, can be engineered to do more than just target specific cells. They can be used flexibly to answer any number of therapeutic challenges, eliminating the need to find compounds that by themselves are both effective therapies and effective delivery systems within the body.One recent thrust has been to develop a nanoparticle without using organic solvents because the solvents react with some types of therapeutic drugs, breaking them down before they can enter the bloodstream. Another effort, in collaboration with Langer and Richard Blumberg, a professor of medicine at HMS and the Brigham, has been to develop a particle that can be taken orally. The process mimics the natural process through which infants gain the antibodies that give them their initial protection on entering the world. The babies absorb the antibodies in their mother’s breast milk, and the antibodies cross the gut/blood barrier to give them immune protection. When nanoparticles are attached to antibodies, they can hitch a ride into the bloodstream through a barrier they couldn’t cross alone.“If oral delivery of biologics is so difficult, why do babies do it so effectively?” Farokhzad asked.
Kickoffs in college football have the potential to become some of the most exciting plays in the sport. A return to the house can reverse the momentum of a game and ignite a previously dreary atmosphere.But it is P.J. Rosowksi’s job to prevent just that. Rosowski, the University of Wisconsin football team’s kickoff specialist, maintains the goal of depositing the ball deep into the end zone or beyond for a touchback, thus preventing a return and the possibility of a game-changing play, thus forcing opponents to begin their drives from the 25-yard line.Rosowski said a touchback is his goal every time he winds up a kickoff, unless he has instructions from the coaching staff to utilize a different kicking tactic, such as kicking it high and allowing the coverage team to pin the ball closer to the opposition’s goal line, or executing a squib kick.“I know probably as soon as I hit it where it’s going to be and where it’s going,” Rosowski said.The key to a perfect kickoff, he said, is keeping his eyes trained on the exact spot he desires his foot to connect with the leather of the football. That method has proved to be effective this season. On Rosowski’s 54 kickoff attempts, he has forced a touchback 34 times (62.9 percent). Only Iowa’s Ron Colluzi (69.4 percent) forces touchbacks at a higher clip in the Big Ten. For Wisconsin, it is a dramatic increase from last season, when UW only recorded touchbacks on 13 of its 71 kickoffs.UW head coach Paul Chryst said Rosowski’s effectiveness is a boon for the Badgers.“What he’s done and contributed has been really good for our team,” Chyrst said. “So often, you hear about hitting yards and I think that’s an area where you don’t have to stress every time you’re covering a kickoff, because we know the potential for a big play that kickoff returns have.”When Chryst says that, he means Iowa’s Desmond King’s return toward the end of UW’s 17-9 win in Iowa City on Oct. 22. King reeled off a 77-yard return, setting the Hawkeyes up in prime field position. Prior to that return, the Badgers had allowed only 14.7 yards per return, which had ranked first in the nation. Now, Wisconsin averages 17.9 yards per return.The art of kickoffs can seem monotonous — simply lining up and kicking the ball as far as you can. But Rosowski said he keeps it fresh by trying to bring energy to every kick. Also, he spends a good deal of time on his specialty kicks, like onsides or squibs.Chryst said he always knew Rosowski had a strong leg and would put himself in position for this opportunity. He saw that much during practices, but wasn’t sure how it would translate to the games.“It’s been fun to see what he’s been doing and I know guys on the team appreciate it. He works at it,” Chryst said. “He takes it seriously. It’s fun to see him have his niche. He’s truly contributing, and in many ways, in a big way.”Challenges Rosowski will face as the season goes on, Chryst said, is the colder weather approaching, which hardens the ball and makes it harder to kick.Rosowksi challenged freshman Anthony Lotti for primary punting duties during training camp, and while Lotti has taken that role, Rosowski still contributes in that aspect of the game. Rosowski said the competition — past and present — brings out the best between the two of them.“There’s always guys pushing each other and I think that’s the best thing about this team,” he said.
The weapon looks better suited at destroying builds rather than damaging opponents, but it can certainly do the latter.How to use Air Strike in FortniteSome details from Epic Games regarding the Air Strike: Fortnite released its 9.30 Content Update and in the patch notes, Epic Games introduced an interesting new weapon: Air Strike.The tagline for Air Strike is: “Throw this down to get help from above!” In a video released for the new item, it shows a user throwing the Air Strike canister into an enemy’s base, releasing a red smoke in the surrounding area. A few moments later, explosives start going off from above firing down in different directions. A thrown canister of colored smoke that calls in a flurry of missiles from above.Once the canister comes to rest, missiles will spawn after a short delay.Missiles spawn about 120 meters above the smoke canister.Missiles aim for random points within a 9 meters radius of the thrown object. A total of 20 missiles are spawned.Each missile has an explosion radius of 3.5 meters.Each missile deals 75 damage to players and 200 damage to structures.Can be found from Floor Loot, Chests, Supply Drops, Vending Machines, and Llamas.Drops in stacks of 1.Max stack size of 2.Legendary variant.Air Strike reaction from Fortnite playersIt didn’t take long after Fortnite’s announcement of the Air Strike for gamers to voice their complaints. Ah yes. More items that take no skill. Keep’em coming— Avery (@Avxry) July 9, 2019Epic about to add AIR STRIKES to Fortnite two weeks before players compete for 30 million dollarsvery cool pic.twitter.com/Gk80ciwPfb— Rod Breslau (@Slasher) July 9, 2019Remove it from competitive— FOV slider and old factories back for season 10 (@Cypnos) July 9, 2019U joking right?— code:Mr-Savage-M (@MrSavage) July 9, 20192 weeks before a $30 million tourney btw— JewishLewish (@JewishLewish) July 9, 2019no— Sceptic (@Sceptic) July 9, 2019yeah nah im good thanks— McCreamy (@McCreamy) July 9, 2019A lot of the complaints are due to the fact the Fortnite World Cup is coming up in just a few weeks. The tournament has a $30 million prize pool, so introducing a brand new weapon like this just before the tournament has caused some understandable frustration. Epic Games has been understanding of some of these complaints, removing items from competitive play (such as the Storm Flip) as they work on a solution to make it acceptable. We’ll have to wait and see how competitive players will react to the Air Strike item in Arena mode.
Welcome our newest advertiser, Â Ray’s Diner, located at 1617 N. A Street (formerly A&W). Â Now open 7 days a week from 8 a.m. – 9 p.m serving daily specials for breakfast, lunch and dinner.Â Call in orders always welcome: Â 620-326-3333.Join us for our Grand Opening and Ribbon Cutting Ceremony on July 11 atÂ 8Â p.m.Â after the Wheat Festival “Cruising Main Street” event. Â Â Visit Ray’s Facebook page to see their delicious pies and other menu items. Â